Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm

Core Viewpoint - The Gross Law Firm is notifying shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to allegations of misleading statements about the company's lead product candidate, nimacimab, which was claimed to be less effective than represented [1][2]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [1]. - Allegations include that the defendants made materially false and misleading statements about nimacimab's effectiveness and overstated its clinical, regulatory, and commercial prospects [1]. - Shareholders are encouraged to register for the class action and can do so without any cost or obligation [2]. Group 2: Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - The deadline to seek lead plaintiff status is January 16, 2026 [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].